Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$212.15 USD

212.15
651,165

+1.37 (0.65%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $211.69 -0.46 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Align (ALGN) Gains From Growing Invisalign Volume, Innovation

by Zacks Equity Research

Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America.

Down -14.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Align Technology (ALGN)

by Zacks Equity Research

Align Technology (ALGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

3 Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

DexCom (DXCM) Launches Latest CGM Sensor ONE in France

by Zacks Equity Research

DexCom's (DXCM) latest CGM sensor, DexCom ONE, secures reimbursement coverage in France, bringing the real-time CGM sensor to half a million diabetes patients in the country.

Here's Why You Should Retain Fresenius Medical (FMS) for Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Here's Why You Should Retain Cencora (COR) Stock for Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why You Should Retain DexCom (DXCM) Stock for Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Are Medical Stocks Lagging Brainsway (BWAY) This Year?

by Zacks Equity Research

Here is how Brainsway Ltd. Sponsored ADR (BWAY) and Align Technology (ALGN) have performed compared to their sector so far this year.

Here's Why Align Technology (ALGN) is Poised for a Turnaround After Losing -10.74% in 4 Weeks

by Zacks Equity Research

Align Technology (ALGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Stryker (SYK) Gets FDA 501k Clearance for Pangea Trauma Systems

by Zacks Equity Research

Stryker's (SYK) Pangea systems will boost the company's Trauma business unit following a complete launch. SYK plans to present the new system at the Annual Orthopaedic Trauma Association meeting.

DexCom (DXCM) Rises 7% in One Week: What's Driving It?

by Zacks Equity Research

DexCom's (DXCM) shares have rallied nearly 7% over the past week, presumably on positive outlook for its CGM devices amid rising competition.

Reasons to Retain Baxter International (BAX) in Your Portfolio

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Align Technologies (ALGN) Brings New Upgrades for Oral Health

by Zacks Equity Research

Align Technologies (ALGN) introduces a series of software innovations to accelerate the digital practice transformation.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RSPH

Here's Why You Should Retain Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Bruker (BRKR), backed by the performance of the CALID and NANO groups and strength in acquisitions.

Align Technology's (ALGN) New Feature to Boost Patient Experience

by Zacks Equity Research

Align Technology's (ALGN) introduction of the new SmartForce feature is expected to minimize the number of attachments while maintaining predictable treatment outcomes.

Align Technologies (ALGN) Set to Acquire Cubicure GmbH

by Zacks Equity Research

Align Technologies (ALGN) announces acquisition of direct 3D printing pioneer Cubicure GmbH, backed by years of successful collaboration.

Merit Medical's (MMSI) Aspira Bottle to Boost At-Home Services

by Zacks Equity Research

Merit Medical (MMSI) launches Aspira Bottle, complementing its Aspira Drainage System, that can provide compassionate home treatment option for critical cancer and other patients.

Henry Schein (HSIC) Down 1.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL), owing to the strong prospect of the advanced services portfolio.

Why You Should Add Haemonetics (HAE) to Your Portfolio Now

by Zacks Equity Research

Haemonetics' (HAE) share price is likely to grow, backed by solid business performance across all its segments.

Revvity (RVTY) Launches Three New Preclinical Research Systems

by Zacks Equity Research

Revvity (RVTY) launches new preclinical imaging technologies for breakthrough discoveries. Learn how they can help advance research and boost Revvity's prospect.

DexCom's (DXCM) G6 CGM Connects With Omnipod 5 AID in Germany

by Zacks Equity Research

DexCom's (DXCM) G6 CGM system and Omnipod 5 AID system can now simplify diabetes management and improve health outcomes in Germany.